Concepedia

90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Patrice Chevallier, Thomas Eugène, Nelly Robillard, Françoise Isnard, Franck Nicolini, Martine Escoffre‐Barbe, Françoise Huguet, Mathilde Hunault, Antoine Marçais, Joëlle Gaschet,

The Lancet Haematology · 2015 · 44 citations · 26 references

DOI

Concepts

References

26

Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis

Mónica Garcı́a-Barros, François Paris, Carlos Cordon‐Cardo et al. · Science · 2003 · 1.6K citations

, , +17

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Adele K. Fielding, Susan Richards, Rajesh Chopra et al. · Blood · 2006 · 843 citations · Full text

, , +9

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Nicola Gökbuget, Daniel Stanze, Joachim Beck et al. · Blood · 2012 · 465 citations · Full text

, , +14

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · The Lancet Oncology · 2012 · 412 citations

, , +14

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Albert Oriol, Susana Vives, Jesús María Hernández‐Rivas et al. · Haematologica · 2010 · 292 citations · Full text

, , +14